IDO1 and neoplasm: Although inhibition of IDO in murine tumor models stimulated the T cell-mediated anti-tumor responses [247,248], a recent phase III study of the direct IDO inhibitor, epacadostat, failed to further increase the progression-free survival in combination with anti-PD-1 therapy over anti-PD-1 monotherapy [249].